BMS and Microsoft Partner to Advance AI-Driven Lung Cancer Detection
Bristol Myers Squibb (BMS) and Microsoft announced a collaboration on January 20, 2026, to deploy FDA-cleared AI radiology tools via Microsoft's Precision Imaging Network, used by over 80% of U.S. hospitals, for faster non-small cell lung cancer (NSCLC) detection.123
The AI analyzes X-ray and CT images to identify hard-to-detect lung nodules, speeding diagnosis, reducing radiologist workload, and improving patient triage to care pathways.123
Focus on underserved areas like rural hospitals and community clinics to address disparities in lung cancer outcomes, where ~227,000 new U.S. cases and 125,000 deaths occur annually.13
BMS markets Opdivo for NSCLC; earlier detection could expand treatment access.1
Quotes:
BMS's Dr. Alexandra Goncalves on combining expertise for efficient workflows; Microsoft's Peter Durlach on early symptom identification.13
Sources:
1. https://www.fiercebiotech.com/medtech/bristol-myers-squibb-signs-microsofts-ai-detection-network-speedy-lung-cancer-diagnosis
2. https://www.pharmaceutical-technology.com/news/bms-microsoft-partner-cancer-detection/
3. https://opendatascience.com/bristol-myers-squibb-partners-with-microsoft-to-advance-ai-driven-lung-cancer-detection/